Transforming Drug Access
Alex discusses the ambitious goal of partnering with major branded pharmaceutical companies while already making strides with generic manufacturers. The rapid growth in bulk sales to health systems and clinics highlights a successful pivot to meet demand. With exciting developments on the horizon, the blend of opportunistic action and a long-term vision positions Cost Plus Drugs as a transformative force in the industry.In this clip
From this podcast
Masters of Scale
Rapid Response: How Cost Plus Drugs is revolutionizing pharma, with CEO Alex Oshmyansky
Related Questions